MedTrace Logo

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

NCT05851066 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-09-12

No results posted yet for this study

Summary

This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst

Conditions

  • Dyslipidemias
  • Familial Hypercholesterolemia
  • Hypertriglyceridemia

Interventions

DRUG

VSA003

sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg

DRUG

0.9% NaCl

placebo

Sponsors & Collaborators

  • Visirna Therapeutics HK Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-05-07
Completion
2024-05-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05851066 on ClinicalTrials.gov